Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31444560 | 0.84 | KDM1A (0.43) | MEN1KMT2AKDM1AKDM1BKDM4E | |
| SCHEMBL29081228 | 0.79 | RAD52 (0.54) | KDM1AKDM4ERAD52HTR2CHTR2B | |
| SCHEMBL29347989 | 0.79 | RAD52 (0.54) | KDM1AKDM4ERAD52HTR2CHTR2B | |
| SCHEMBL29585972 | 0.77 | KDM1A (0.45) | MEN1KMT2AKDM1AKDM1BKDM4E | |
| SCHEMBL21523791 | 0.77 | KDM1A (0.45) | MEN1KMT2AKDM1AKDM1BKDM4E | |
| SCHEMBL24367125 | 0.77 | HTR2C (0.49) | MEN1KMT2AKDM4EGAAHTR2C | |
| SCHEMBL24233795 | 0.74 | SMN1; SMN2 (0.42) | MEN1KMT2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL14359968 | 0.74 | SMN1; SMN2 (0.42) | MEN1KMT2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL30471218 | 0.74 | SMN1; SMN2 (0.42) | MEN1KMT2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL1335194 | 0.73 | MEN1 (0.38) | MEN1KMT2AKDM1AKDM1BCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MEN1 142/4885KMT2A 4008/4885KDM1A 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.